Infectious Disease vs Metabolic — Deal Terms Comparison

Infectious Disease Median Upfront

$604M

Total: $2.3B

Metabolic Median Upfront

$935M

Total: $4.5B

Infectious Disease Royalties

8.1%-16.3%

Tiered to 20.3%

Metabolic Royalties

16.1%-29.5%

Tiered to 33.5%

Model Your Deal

Market Analysis

Infectious Disease and Metabolic represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 infectious disease deals carry a median total deal value of $2.3B with $604M upfront, compared to $4.5B total value and $935M upfront for metabolic. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Infectious Disease deals allocate 26% to upfront and 74% to milestones, while Metabolic deals split 21%/79%. Development milestones are $376M for infectious disease versus $647M for metabolic, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do infectious disease and metabolic deal terms compare?

Infectious Disease Phase 2 deals average $2.3B total value ($604M upfront), while Metabolic deals average $4.5B ($935M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Infectious Disease or Metabolic?

Infectious Disease base royalties range from 8.1% to 16.3%, while Metabolic royalties range from 16.1% to 29.5%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between infectious disease and metabolic?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Infectious Disease and Metabolic each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included